319 related articles for article (PubMed ID: 28151871)
21. Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use.
Bakris GL; Burkart JM; Weinhandl ED; McCullough PA; Kraus MA
Am J Kidney Dis; 2016 Nov; 68(5S1):S15-S23. PubMed ID: 27772639
[TBL] [Abstract][Full Text] [Related]
22. β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Zhou H; Sim JJ; Shi J; Shaw SF; Lee MS; Neyer JR; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ
Am J Kidney Dis; 2021 May; 77(5):704-712. PubMed ID: 33010357
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
Ferreira JP; Couchoud C; Gregson J; Tiple A; Glowacki F; London G; Agarwal R; Rossignol P
Nephrol Dial Transplant; 2019 Jul; 34(7):1216-1222. PubMed ID: 30590716
[TBL] [Abstract][Full Text] [Related]
24. Drug therapy for hypertension in hemodialysis patients.
Hörl MP; Tepel M
Minerva Med; 2005 Aug; 96(4):277-85. PubMed ID: 16179894
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
26. Heart failure as a cause for hospitalization in chronic dialysis patients.
Trespalacios FC; Taylor AJ; Agodoa LY; Bakris GL; Abbott KC
Am J Kidney Dis; 2003 Jun; 41(6):1267-77. PubMed ID: 12776280
[TBL] [Abstract][Full Text] [Related]
27. Antihypertensive agents in hemodialysis patients: a current perspective.
Inrig JK
Semin Dial; 2010; 23(3):290-7. PubMed ID: 20374548
[TBL] [Abstract][Full Text] [Related]
28. Beta-blockers for hypertension.
Wiysonge CS; Bradley H; Mayosi BM; Maroney R; Mbewu A; Opie LH; Volmink J
Cochrane Database Syst Rev; 2007 Jan; (1):CD002003. PubMed ID: 17253471
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
30. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
31. Impact of race on cumulative exposure to antihypertensive medications in dialysis.
Wetmore JB; Mahnken JD; Rigler SK; Ellerbeck EF; Mukhopadhyay P; Hou Q; Shireman TI
Am J Hypertens; 2013 Feb; 26(2):234-42. PubMed ID: 23382408
[TBL] [Abstract][Full Text] [Related]
32. Beta-blockers for hypertension.
Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
[TBL] [Abstract][Full Text] [Related]
33. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
[TBL] [Abstract][Full Text] [Related]
34. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider.
Manley HJ; Garvin CG; Drayer DK; Reid GM; Bender WL; Neufeld TK; Hebbar S; Muther RS
Nephrol Dial Transplant; 2004 Jul; 19(7):1842-8. PubMed ID: 15128886
[TBL] [Abstract][Full Text] [Related]
35. Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis.
Rhee CM; Kovesdy CP; You AS; Sim JJ; Soohoo M; Streja E; Molnar MZ; Amin AN; Abbott K; Nguyen DV; Kalantar-Zadeh K
Am J Kidney Dis; 2018 Nov; 72(5):701-710. PubMed ID: 30037725
[TBL] [Abstract][Full Text] [Related]
36. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
Shih CJ; Chen HT; Chao PW; Kuo SC; Li SY; Yang CY; Tarng DC; Ou SM; Chen YT
J Hypertens; 2016 Mar; 34(3):567-74; discussion 575. PubMed ID: 26703918
[TBL] [Abstract][Full Text] [Related]
38. Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months.
St Peter WL; Sozio SM; Shafi T; Ephraim PL; Luly J; McDermott A; Bandeen-Roche K; Meyer KB; Crews DC; Scialla JJ; Miskulin DC; Tangri N; Jaar BG; Michels WM; Wu AW; Boulware LE;
BMC Nephrol; 2013 Nov; 14():249. PubMed ID: 24219348
[TBL] [Abstract][Full Text] [Related]
39. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
Portolés J; López-Gómez JM; Aljama P
Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
[TBL] [Abstract][Full Text] [Related]
40. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
Lee HF; See LC; Chan YH; Yeh YH; Wu LS; Liu JR; Tu HT; Wang CL; Kuo CT; Chang SH
Intern Med J; 2018 Sep; 48(9):1123-1132. PubMed ID: 29808610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
